Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00353561
Status:
COMPLETED
Last Update Posted:
2008-05-22
First Post:
2006-07-17
Brief Title:
Diabetes Mellitus and Vulvovaginal Candidiasis
Sponsor:
Indian Council of Medical Research
Organization:
Indian Council of Medical Research
Study Overview
Official Title:
Diabetes Mellitus and Vulvovaginal Candidiasis Prevalence of Infection and Its Rationale Management
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clinical and mycological response to oral fluconazole and boric acid suppositories was assessed in patients with diabetes mellitus and vulvovaginal candidiasis
Detailed Description:
A high proportion of vulvovaginal candidiasis is due to Cglabrata that responds poorly to fluconazole therapy We assessed the clinical relief and mycological cure in response to oral fluconazole and boric acid suppositories in patients with diabetes mellitus and vulvovaginal candidiasis given in a Randomized trial Fluconazole was given in standard oral single dose 150 mg fluconazole and boric acid vaginal suppositories was given in dose of 600 mgdaily for 14 uninterrupted days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None